Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
TScan Therapeutics ( (TCRX) ) has issued an update.
On November 25, 2025, TScan Therapeutics‘ Board of Directors approved a retention program to secure key employees, including its CEO, CFO, and CMO, with cash and equity-based awards. This initiative aims to support the company’s operations and advance the pivotal trial of TSC-101, potentially impacting its market position and stakeholder interests.
The most recent analyst rating on (TCRX) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on TScan Therapeutics stock, see the TCRX Stock Forecast page.
Spark’s Take on TCRX Stock
According to Spark, TipRanks’ AI Analyst, TCRX is a Neutral.
The overall stock score for TScan Therapeutics is primarily impacted by its financial performance, which shows strong revenue growth but significant profitability and cash flow challenges. The technical analysis indicates bearish momentum, and the valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors collectively contribute to a low overall score.
To see Spark’s full report on TCRX stock, click here.
More about TScan Therapeutics
TScan Therapeutics, Inc. operates in the biotechnology industry, focusing on developing T-cell receptor-engineered T-cell therapies for the treatment of cancer.
Average Trading Volume: 672,186
Technical Sentiment Signal: Sell
Current Market Cap: $55.53M
See more data about TCRX stock on TipRanks’ Stock Analysis page.